QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Maddux, F. W Articles by Murray, B. M Search for Related Content PubMed PubMed Citation Articles by Maddux, F. W Articles by Murray, B. M

PHARMACOECONOMICS

Effect of Erythropoiesis-Stimulating Agents on Healthcare Utilization, Costs, and Outcomes in Chronic Kidney Disease

Senior Vice President and Chief Medical Officer, Specialty Care Services Group, Nashville, TN

Sharashchandra Shetty, PhD

Associate Director, i3 Innovus, Eden Prairie, MN

Michael A del Aguila, PhD

Therapeutic Area Director, Medical Data Analytics, Roche Laboratories, Inc., Nutley, NJ

Michael A Nelson, PharmD BCPS

Regional Vice President, Health Economics and Outcomes Research, i3 Innovus

Brian M Murray, MD FACP FRCPI

Associate Medical Director, Erie County Medical Center, Buffalo, NY

Reprints: Dr. Maddux, Specialty Care Services Group, 3100 West End Ave., Suite 150, Nashville, TN 37203, fax 615/345-5565, frank.maddux{at}specialtycaresg.com

BACKGROUND: Anemia commonly complicates chronic kidney disease (CKD). Treating anemia of CKD with erythropoiesis-stimulating agents (ESAs) may attenuate cardiovascular and renal sequelae, reducing morbidity, mortality, and healthcare costs.

OBJECTIVE: To compare clinical outcomes, healthcare utilization, and costs in ESA-treated and untreated patients with anemia of CKD who are not on dialysis.

METHODS: This retrospective claims analysis considered more than 13 million US health plan members for outpatient, inpatient, emergency department, and prescription experience. Eligible patients were aged 15 years or older with 2 or more ICD-9 diagnoses of CKD or 1 or more CKD diagnosis and 1 or more claims for ESA within 12 months. The first CKD diagnosis within the study period (January 1, 2000-December 31, 2003) defined the index date. Anemia was ascertained by ICD-9 codes or ESA claims on or after the CKD index date. Patients were censored for dialysis, transplant, inpatient death, disenrollment, or study end. Utilization and costs per patient per month were compared between ESA and non-ESA patients. Generalized linear modeling identified predictors of total and anemia-related costs.

RESULTS: Of 26,244 patients with CKD, 8188 (31.2%) had anemia; of those, only 14.6% (n = 1197) received ESAs. ESA recipients had lower total monthly healthcare costs than did untreated anemic patients ($3876 vs $4758; p = 0.0061). Lower monthly inpatient and emergency department costs in treated versus untreated anemic patients ($2507 vs $3849 and $46.56 vs $81, respectively; both p < 0.0001) outweighed higher outpatient and laboratory costs from ESA use ($602 vs $397 and $23.50 vs $14.34, respectively; both p < 0.0001). Multivariate analysis revealed that ESA users had lower adjusted monthly total costs ($2962 vs $3373) compared with non-ESA patients.

CONCLUSIONS: ESA use was associated with mean total cost savings of $411 per patient per month, reflecting reduced inpatient and emergency department visits and costs, and with lower inpatient mortality and longer time to dialysis. The low (14.6%) ESA treatment rate for anemia highlights the continuing deficit in CKD care.

Key Words: chronic kidney disease, darbepoetin alfa, epoetin alfa, erythropoiesis-stimulating agents, predialysis

Published Online, September 25, 2007. www.theannals.com, DOI 10.1345/aph.1K194